Research
Vinpocetine
35 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Safety and Efficacy of Vinpocetine as a Neuroprotective Agent in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
Systematic review and meta-analysis of vinpocetine as a neuroprotective agent in acute ischemic stroke. Four RCTs with 601 vinpocetine and 236 placebo patients showed reduced disability in the vinpocetine group at 1 and 3 months. However, evidence is insufficient to confirm reduced case fatality, and more RCTs are needed.
Vinpocetine for cognitive impairment and dementia.
Meta-analysis of vinpocetine for cognitive impairment and dementia, including 583 patients across three studies. Results show some benefit with vinpocetine 30mg/day and 60 mg/day compared to placebo, but evidence is inconclusive and does not support clinical use. Adverse effects were inconsistently reported.
Evaluation of vinpocetine as a therapy in patients with sensorineural hearing loss: A phase II, open-label, single-center study.
Phase II, open-label study evaluating vinpocetine as a treatment for acquired sensorineural hearing loss over 12 months. Results showed that vinpocetine helped stop hearing impairment and even improved hearing capacity in patients.
Combination of Vinpocetine and Dexamethasone Alleviates Cognitive Impairment in Nasopharyngeal Carcinoma Patients following Radiation Injury.
RCT involving 60 NPC patients with radiation-related brain injury, comparing dexamethasone monotherapy to a combination of vinpocetine and dexamethasone. The combination therapy lowered serum inflammatory cytokines, increased antioxidants, decreased oxidants, and significantly improved cognitive function as measured by the Mini Mental State Examination score.
Efficacy and Safety of Vinpocetine as Part of Treatment for Acute Cerebral Infarction: A Randomized, Open-Label, Controlled, Multicenter CAVIN (Chinese Assessment for Vinpocetine in Neurology) Trial.
RCT evaluating the efficacy and safety of intravenous vinpocetine in 610 acute cerebral infarction patients. The vinpocetine group showed significantly improved cognitive skills, neurological function, and quality of life compared to the control group, with increased cerebral blood flow and no significant difference in safety.
Vinpocetine for acute ischaemic stroke.
Systematic review assessing the effect of vinpocetine in acute ischaemic stroke. Included two trials with a total of 70 participants, reporting data for 63. No difference in death or dependency between treatment and placebo groups at one and three months. Evidence is insufficient to evaluate vinpocetine's effect on survival or dependency.
[The role of vinpocetine in the treatment of cerebrovascular diseases based in human studies].
This meta-analysis reviews the effects of vinpocetine in acute and chronic cerebrovascular diseases. While vinpocetine shows limited evidence of benefit in acute ischemic stroke, it significantly improves cerebral blood flow, metabolism, and cognitive achievement in chronic cerebrovascular patients.
Vinpocetine, cognition, and epilepsy.
RCT assessed cognitive effects of vinpocetine in 8 healthy volunteers and 8 patients with epilepsy using a double-blind, randomized, crossover design. No significant cognitive benefits were observed. Vinpocetine and AVA levels were lower in humans than in animals, suggesting higher dosages may be needed for efficacy.
Extended-release vinpocetine: a possible adjuvant treatment for focal onset epileptic seizures.
A double-blind RCT evaluated the efficacy and tolerability of extended-release vinpocetine as an adjuvant treatment for focal onset epileptic seizures in 87 patients. Vinpocetine was more effective than placebo in reducing seizures, with 69% of vinpocetine-treated patients experiencing a 50% reduction in seizures compared to 13% of placebo-treated patients. Vinpocetine was well tolerated with a low rate of adverse events.
[Study of the effects of vinpocetin on cognitive functions].
RCT investigating the efficacy and safety of 18 months vinpocetine treatment in patients with mild cognitive impairment. Significant improvements were observed in cognitive functions, overall disease status, daily activity, and mood. Vinpocetine was safe and well-tolerated.
Novel sugar esters proniosomes for transdermal delivery of vinpocetine: preclinical and clinical studies.
The study developed a novel sustained release proniosomal system using sugar esters for transdermal delivery of vinpocetine, aiming to improve its bioavailability. The optimized formula showed high drug permeation and a relative bioavailability of 206% compared to oral tablets, with only moderate skin irritation observed.
[Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions].
The study investigated the effects of 12-week oral vinpocetine therapy on cerebral blood flow and cognitive functions in patients with ischemic stroke and mild cognitive impairment. Vinpocetine significantly improved blood flow velocity and cognitive functions in both patient groups, with patients reporting improved general condition.
[The effect of a single-dose intravenous vinpocetine on brain metabolism in patients with ischemic stroke].
The study investigated the effect of a single-dose intravenous vinpocetine on cerebral blood flow and glucose metabolism in post-stroke patients. While vinpocetine did not significantly affect regional or global metabolic rates of glucose, it strongly affected glucose transport in the brain. Slight changes in cerebral blood flow were observed but were not significant.
Vinpocetine for acute ischaemic stroke.
Systematic review assessing the effect of vinpocetine in acute ischaemic stroke. One trial with 40 patients was included, with data reported for 33 patients. No significant difference in dependency or survival was found between the treatment and placebo groups, and no adverse effects were reported.
A systematic review of vinpocetine therapy in acute ischaemic stroke.
Systematic review aimed to determine if vinpocetine decreases case fatality and dependency in acute ischaemic stroke when administered within 2 weeks of onset. Only one small RCT met inclusion criteria, showing no significant difference in outcomes between vinpocetine and placebo groups.
Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes.
RCT of 203 patients with mild to moderate organic psychosyndromes comparing vinpocetine (30 mg or 60 mg daily) to placebo over 16 weeks. Vinpocetine showed statistically significant improvements in global improvement, cognitive performance, and severity of illness compared to placebo, with no clinically relevant side-effects.
Vinpocetine and pyritinol: a new model for blood rheological modulation in cerebrovascular disorders—a randomized controlled clinical study.
RCT involving 30 patients with cerebrovascular disorders to study the effects of vinpocetine and pyritinol on blood rheological parameters. The combination significantly improved blood and plasma viscosity, particularly at low shear, but had insignificant effects on total serum protein and high shear viscosity.
Transcranial Doppler assessment of cerebral vasomotor reactivity in evaluating the effects of vinpocetine in cerebral small vessel disease: a pilot study.
This pilot study assessed the vasodilating effect of vinpocetine in 30 patients with cerebral small vessel disease over a 3-month period. Vinpocetine treatment increased the breath holding index (BHI) and improved Mini Mental State Examination (MMSE) scores and functional status, suggesting potential benefits for cerebral vasomotor reactivity and brain health.
Effect of parenteral or oral vinpocetine on the hemorheological parameters of patients with chronic cerebrovascular diseases.
The study investigates hemorheological changes in 40 patients with chronic cerebrovascular disease after administration of vinpocetine. High-dose parenteral vinpocetine significantly decreased red blood cell aggregation, plasma, and whole blood viscosity. Oral vinpocetine also resulted in lower plasma and whole blood viscosities compared to placebo at 3 months.
Acute and chronic effects of vinpocetine on cerebral hemodynamics and neuropsychological performance in multi-infarct patients.
A double-blind, prospective, randomized, placebo-controlled clinical trial tested the effects of vinpocetine on cerebral hemodynamics and cognitive performance in 26 patients with multiple cerebral infarcts. Vinpocetine showed lower flow velocities in the acute phase and no significant worsening in the digit span backward test after three months, compared to placebo. No serious side effects were found.
Pharmacokinetics and comparative bioavailability of two vinpocetine tablet formulations in healthy volunteers by using the metabolite apovincaminic acid as pharmacokinetic parameter.
The study evaluated the pharmacokinetics of apovincaminic acid, the main metabolite of vinpocetine, and assessed the bioequivalence of two 10 mg vinpocetine tablet formulations in 24 healthy male volunteers. The test product was found to be bioequivalent to the reference product with respect to the rate and extent of apovincaminic acid pharmacokinetics.
Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study.
Double-blind RCT studying the effects of intravenous vinpocetine on cerebral blood flow and glucose metabolism in 13 chronic ischemic stroke patients. The study found that vinpocetine treatment led to increased global cerebral blood flow and marked changes in regional cerebral metabolic rates of glucose and blood flow, particularly in the thalamus and caudate nucleus.
[Effect of vinpocetin on the hemorheologic parameters in patients with chronic cerebrovascular disease].
RCT investigating hemorheological changes after administration of small (30 mg/day) and high dose (70 mg/day) intravenous vinpocetine for 7 days in 30 patients with chronic ischemic cerebrovascular disease. High dose vinpocetine significantly decreased hematocrit, whole blood and plasma viscosity, and red blood cell aggregation. Small dose improved red blood cell aggregation.
Vinpocetine increases cerebral blood flow and oxygenation in stroke patients: a near infrared spectroscopy and transcranial Doppler study.
Double-blind, placebo-controlled study of 43 ischemic stroke patients assessing the effect of a single-dose i.v. infusion of vinpocetine on cerebral blood perfusion and oxygenation. Vinpocetine increased cerebral perfusion and parenchymal oxygen extraction, as indicated by NIRS and TCD measurements, while conventional velocity and pulsatility measurements did not detect these effects.
Vinpocetine treatment in acute ischaemic stroke: a pilot single-blind randomized clinical trial.
Pilot single-blind randomized clinical trial assessing the safety and feasibility of vinpocetine in acute ischaemic stroke. Thirty patients were treated with either low-molecular weight dextran alone or in combination with vinpocetine. The vinpocetine group showed a relative risk reduction of poor outcome at 3 months follow-up, with marginally significant improvement in NIH Stroke Scale scores.
Initial clinical experience with the selective phosphodiesterase-I isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder.
Initial clinical experience with vinpocetine, a selective PDE-1 inhibitor, in treating urge incontinence and low compliance bladder. In 11 out of 19 patients, clinical symptoms and/or urodynamic parameters improved, suggesting potential for PDE inhibition in lower urinary tract disorders.
The effect of a cerebral vasodilator, vinpocetine, on cerebral vascular resistance evaluated by the Doppler ultrasonic technique in patients with cerebrovascular diseases.
The study examined changes in cerebral vascular resistance in patients with cerebral circulatory diseases using the Doppler ultrasonic technique after administration of vinpocetine for two months. Significant changes in the continuous index (CI) and pulsatility index (PI) were observed, suggesting the technique's usefulness in investigating drug effects on cerebral circulation.
Examinations of the relative fluidity in cerebrovascular disease patients.
The study measured changes in blood viscosity during vinpocetine therapy in cerebrovascular disease patients, comparing it to haematocrit and mean corpuscular volume values. Vinpocetine's effects were also compared with secale alkaloids and pentoxifylline, showing effectiveness in both short and long-term therapy.
A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction.
Double-blind clinical trial evaluating vinpocetine in 84 elderly patients with chronic cerebral dysfunction. Patients receiving vinpocetine showed significant improvement in cognitive assessments compared to placebo, with no serious side effects.
Lack of pharmacokinetic interaction between vinpocetine and oxazepam.
The study investigated the influence of multiple doses of vinpocetine on the steady state plasma concentrations of oxazepam in 16 healthy subjects. Results showed no significant pharmacokinetic interaction between vinpocetine and oxazepam, with similar AUC values for oxazepam alone and in combination with vinpocetine.
Vinpocetine effects on cognitive impairments produced by flunitrazepam.
RCT studying the effects of vinpocetine 40 mg pre-treatment on flunitrazepam-induced memory impairment in 8 normal volunteers. Vinpocetine was associated with improvements in short-term memory processes, though drug effects were modest.
Psychopharmacological effects of vinpocetine in normal healthy volunteers.
RCT with 12 healthy female volunteers testing vinpocetine at doses of 10, 20, 40 mg and placebo. No significant changes were observed on CFF, CRT, or subjective ratings, but memory was significantly improved with vinpocetine 40 mg compared to placebo, suggesting a localized effect on the serial comparison stage of the reaction process.
Open-labeled phase III clinical trials with vinpocetine in Japan.
The paper reports on open-labeled phase III clinical trials with vinpocetine conducted in Japan. No abstract is available to provide further details on the findings or specific goals studied.
Drug distribution in man: a positron emission tomography study after oral administration of the labelled neuroprotective drug vinpocetine.
The study used positron emission tomography (PET) to measure the distribution of the neuroprotective drug vinpocetine in the human body after oral administration. Vinpocetine, labelled with carbon-11, was tracked in various tissues including the stomach, liver, brain, and kidneys in six healthy volunteers, demonstrating its ability to enter the bloodstream and pass the blood-brain barrier.
PET studies on the brain uptake and regional distribution of [11C]vinpocetine in human subjects.
The study used positron emission tomography to examine the brain uptake and regional distribution of [11C]vinpocetine in three healthy subjects. Vinpocetine was found to rapidly pass the blood-brain barrier with heterogeneous distribution among brain regions, suggesting direct neuronal actions.